## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

A'TTY. DOCKET NO. 52494/2101	SERIAL NO. 10/79146		
APPLICANT James M. MASON			
FILING DATE Herewith 3/1/2004	GROUP /636 Not Yet Assigned		

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
or	4,405,712	9/20/83	Vande Woude et al.		$\times$	7/1/81
97	5,562,904	10/8/96	Rother et al.			7/21/94
01	5,576,201	11/19/96	Mason et al.	1.		1/14/94
09	5,580,766	12/3/96	Mason et al.	X	$X \rightarrow$	1/14/94
97	5,643,770	7/1/97	Mason et al.	$\cdot$		7/21/94
27	5,871,997	2/16/99	Rother et al.			
R	6,329,199 B1	12/2001	Pensiero et al.		X X	

<sup>• -</sup> If pertinent

## FOREIGN PATENT DOCUMENTS

EVALORED	DOCUM (E) IT					TRANSL	ATION
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	Ю
197	WO89/07150	8/10/89	PCT				
er	WO92/07943	5/14/92	PCT				
or	EP 0178,220	4/16/86	EPO				

## OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
091	Anderson et al., "Endogenous Origin of Defective Retroviruslike Particles from a Recombinant Chinese Hamster Ovary Cell Line," Virology, vol. 181, pp. 305-311 (1991).
91	Anderson, Nature, 1998, Vol.392, pp. 25-30
or	Chong & Vile, "Replication-Competent Retrovirus Produced by a 'Split-function' Third Generation Amphotropic Packaging Cell Line", Gene Ther., 3:624-629, 1996.

EXAMINER	Da	ing Young	DATE CONSIDERED	10/21/05
EXAMINER: In	itial if citation con	oridered whether or not station is in conformance with M	P.F.P. 609: draw line through citation if not in confo	mance and not

considered. Include copy of this form with next communication to applicant.

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
H	Cone & Mulligan, "High-efficiency Gene Transfer into Mammalian Cells: Generation of Helper-free Recombinant Retro Virus with Broad Mammalian Host Range", Proc. Nat'l. Acad. Sci. USA, 81:6349 6353, 1984.
97	Cosset, et al., "High-titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum", J. Virol., 69:7430-7436, 1995.
Pr.	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstracles to Success", Science, 270:404-410, 1995.
07	Culver, et al., "In Vivo Gene Transfer with Retroviral Vector-producer Cells for Treatment of Experimental Brain Tumors", Science, 256:1550-1552, 1992.
91	Eglitis, "Positive Selectable Markers for Use with Mammalian Cells in Culture", Hum. Gene Ther., 2:195-201, 1991.
01	Eglitis & Anderson., "Retroviral Vectors for Introduction of Genes into Mammalian Cells", Biotechniques, 6:608-614, 1988.
87	Fox, Nature Biotechnology, 2000, Vol. 18, pp. 143-144.
01	Galili, et al., "Evolutionary Relationship Between the Natural Anti-gal Antibody and the Galα-3gal Epitope in Primates", Proc. Nat'l. Acad. Sci. USA, 84:1369-1373, 1987.
01	Gilboa, et al., "Transfer and Expression of Cloned Genes Using Retroviral Vectors", Biotechniques, 4:504-512, 1986.
07	Girod, et al., "Homotogous and Nonnomologous Retroviral Recombinations Are Both Involved in the Transfer by Infectious Particles of Defective Avian Leukosis Virus-derived Transcomplementing Genomes, J. Virol., 70:5651-5657, 1996.
91	Hoshino, et al., "Human T-cell Leukemia Virus Is Not Used by Human Serum", Nature, 310:324-325, 1984.
197	Kmiec, American Scientist, 1999, Vol. 87, pp. 240-247
7	Lie et al., J. Virol., 1994, Vol. 68, No. 12, pp. 7840-7849.
97 77 Z	Mann, et al., "Construction of a Retrovirus Packaging Mutant and its Use to Produce Helper-free Defective Retrovirus", Cell, 33:153-159, 1983.
91	Marshall, Science, 2003, Vol. 299, No. 5605, p. 320.
07	Martinez & Dornberg, "Partial Reconstitution of a Replication-competent Retro Virus in Helper Cells with Partial Overlaps Between Vector and Helper Cell Genomes", Hum. Gene Ther., 7:705-712, 1996.
67	Miller, "Human Gene Therapy Comes of Age", Nature, 357:455-460, 1992.
M	Miller & Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques, 7:980-990, 1989.
OZ.	Morgenstern & Land, "Advanced Mammalian Gene Transfer: High Titre Retroviral Vectors with Multiple Drug Selection Markets and a Complementary Helper-free Packaging Cell Line", Nucleic Acds Res., 18:3587-3596, 1990.
01	Mountain, TIBTECH, 2000, Vol. 18, pp. 119-128.
192	Mulligan, "The Basic Science of Gene Therapy", Science, 260:926-932, 1993.

EXAMINER	David Lung	DATE CONSIDERED 10/21/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

666513

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
8	Neethling, et al., "Protection of Pig Kidney (Pk15) Cells from the Cytotoxic Effect of Anti-pig Antibodies by A-galactosyl Oligosaccharides", Transplant; 57:959-963, 1994.
01	Paillard, Human Gene Therapy, 1998, Vol. 9. pp. 767-768.
01	Pensiero, et al., "Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human Serum", Hum. Gene Ther., 7:1095-1101, 1996.
01	Rem, et al., "Toxicity Studies of Retro Viral-mediated Gene Transfer for the Treatment of Brain Tumors", J. Neurosurg., 79:400-407, 1993.
07	Rollins, et al., "Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response", Hum, Gene Ther., 7:619-626, 1996.
91	Rother, et al., "Protection of Retroviral Vector Particles in Human Blood Through Complement Inhibition", Hum. Gene Ther., 6:429-435, 1995.
69	Rother, et al., "A Novel of Retrovirus Inactivation in Human Serum Mediated by Anti-α-galactosyl Natural Antibody", J. Exp. Med., 182:1345-1355, 1995.
69	Rother & Squinto., "The α-galactosyl Epitope: a Sugar Coating That Makes Viruses and Cells Unpalatable", Cell, 86:185-188,1996.
91	Russell, et al., "The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines", Hum. Gene Ther., 6:635-641, 1995.
61	Takeuchi, et al., "Sensitization of Cells and Retroviruses to Human Serum by (α1-3) Galactosyltransferase", Nature 379:85-88, 1996.
61	Takeuchi, et al., "Sensitization of Rhabdo-, Lenti-, and Spumaviruses to Human Serum by Galactosyl (α1-3) Galactosylation", J. Virol., 71:6174-6178, August 1997.
091	Takeuchi, et al., "Type C Retrovirus Inactivation by Human Complement Is Determined by Both the Viral Genome and the Producer Cell", J. Virol., 68:8001-8007, 1994.
es	Verma et al., Nature, 1997, Vol. 389, pp. 239-242.
92	Widner & Brundin, "Immunological Aspects of Grafting in the Mammalian Central Nervous System. A review and speculative synthesis", Brain Res. Rev., 13:287-324, 1988.

EXAMINER	David Dunger	DATE CONSIDERED 10/21/05
		——————————————————————————————————————

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

666513